An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Clinical trial NCT06894511 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06894511
Sponsor: Novartis Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Start date: 2025-09-11
Primary completion: 2026-10-15
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.